Log in to your Inderes Free account to see all free content on this page.
NextCell Pharma
1.78
SEK
-1.66 %
NXTCL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
-1.66%
+1.71%
+41.27%
+25.35%
-14.32%
-23.61%
-71.37%
-42.64%
-19.51%
www.nextcellpharma.com/investerare
NextCell Pharma operates in the healthcare sector. Today, development is carried out of stem cell products mainly used in the treatment of autoimmune diabetes and for kidney transplants. A significant part of the work consists of stem cell research where the company develops drug candidates that should enable and increase the acceptance of organ transplants. In addition, the company has a stem cell bank. The company was established in 2014 and is based in Huddinge.
Revenue
10.66M
EBIT %
-404.97 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
NXTCL
Daily low / high price
1.75 / 1.78
SEK
Market cap
130.1M SEK
Turnover
5.95K SEK
Volume
3.4K
Financial calendar
Interim report
30.01.2025
Interim report
25.04.2025
Interim report
24.07.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 15.6 % | 15.6 % |
| Diamyd Medical AB | 7.2 % | 7.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
NextCell Pharma AB: QVance Announces Partnership
NextCell Pharma AB: QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio